Recursion Pharmaceuticals Inc Cl A (RXRX) Stock Price, Quote & News

Company Profile

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-12...

Industry: Biotechnology

Sector: Healthcare

Phone: 385 269 0203

Website: www.recursion.com

Address:

41 South Rio Grande Street, Salt Lake City, United States

LoveRetailFroth Aug. 19 at 1:59 PM

$RXRX BIG SQUEEZE plays! $TEM $ARBE $AMLX 🚀

0 · Reply

NPNPNP Aug. 19 at 1:46 PM

$RXRX turd will flush after riding a real companies hype

0 · Reply

Crypto99999 Aug. 19 at 1:37 PM

$RXRX Cathie buying more???

0 · Reply

LoveRetailFroth Aug. 19 at 1:36 PM

$TEM Precision Medicine folks!!! $RXRX 🚀🚀

0 · Reply

Oatari Aug. 19 at 1:32 PM

$RXRX

0 · Reply

llGORDll Aug. 19 at 1:29 PM

$RXRX LFG

0 · Reply

Ashok1378 Aug. 19 at 12:32 PM

$RXRX

0 · Reply

Spartangio Aug. 19 at 12:02 PM

$RXRX Look at Moderna - Merck Vicki Goodman helped steer KEYTRUDA’s late-stage oncology journey at Merck — today’s breakthrough is another reminder that $RXRX now has proven oncology leadership at the helm. 🔥 The rest is noise

1 · Reply

LoveRetailFroth Aug. 19 at 11:57 AM

$RXRX Good Morning my Bio 💎s ☕️ $TEM $SANA $AMLX

0 · Reply

Michaela4m Aug. 19 at 11:43 AM

$RXRX

0 · Reply

Recursion Pharmaceuticals Transcript: Bank of America SMID Cap Virtual Conference

Aug 5, 2026, 8:00 AM EDT - 14 days ago

Recursion Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 14 days ago

Recursion Pharmaceuticals Quarterly report: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 14 days ago

Recursion Pharmaceuticals Earnings release: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 14 days ago

Recursion Pharmaceuticals Slides: Q2 2026

Aug 5, 2026, 6:30 AM EDT - 14 days ago

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Aug 4, 2026, 8:00 AM EDT - 15 days ago

Recursion to Participate in Upcoming Investor Conferences

Jul 31, 2026, 4:30 PM EDT - 18 days ago

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Jul 29, 2026, 8:30 AM EDT - 21 days ago

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

Jun 17, 2026, 2:00 PM EDT - 2 months ago

Recursion Pharmaceuticals Transcript: AGM 2026

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Recursion Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

May 19, 2026, 12:07 PM EDT - 3 months ago

Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City

May 12, 2026, 1:00 PM EDT - 3 months ago

Recursion Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 11:49 AM EDT - 3 months ago

These 10 ‘HALO' stocks protect your portfolio from the AI bubble

AWR ES HTO PCG PPL SR SRE

May 6, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Slides: Q1 2026

May 6, 2026, 6:30 AM EDT - 3 months ago

Recursion Reports First Quarter Financial Results and Provides Business Update

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Recursion Announces Board Transition

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Recursion Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 7:59 AM EDT - 4 months ago

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

Apr 13, 2026, 12:45 PM EDT - 4 months ago

Recursion Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Mar 31, 2026, 9:00 AM EDT - 5 months ago

Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

Mar 25, 2026, 7:59 AM EDT - 5 months ago

Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

Mar 17, 2026, 3:45 PM EDT - 5 months ago

Recursion Pharmaceuticals Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 9, 2026, 8:00 AM EDT - 5 months ago

Recursion Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 9:50 AM EST - 6 months ago

Recursion Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 6 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 8:00 AM EST - 6 months ago

Recursion Pharmaceuticals Annual report: Q4 2025

Feb 25, 2026, 8:00 AM EST - 6 months ago

Recursion Pharmaceuticals Earnings release: Q4 2025

Feb 25, 2026, 8:00 AM EST - 6 months ago

Recursion Pharmaceuticals Slides: Q4 2025

Feb 25, 2026, 6:30 AM EST - 6 months ago

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 8:00 AM EST - 6 months ago

Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC

Feb 18, 2026, 8:30 AM EST - 6 months ago

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Feb 18, 2026, 5:43 AM EST - 6 months ago

Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia.

APLD NVDA

Jan 16, 2026, 12:45 PM EST - 7 months ago

Recursion Pharmaceuticals Transcript: 28th Annual Needham Growth Conference Virtual

Jan 13, 2026, 1:30 PM EST - 7 months ago

Recursion Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 1:30 PM EST - 7 months ago

Recursion Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:59 AM EST - 8 months ago

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 11:05 AM EST - 8 months ago

What's Happening With RXRX Stock?

Dec 8, 2025, 8:00 AM EST - 9 months ago

Recursion Pharmaceuticals Transcript: Study Update

Dec 8, 2025, 8:00 AM EST - 9 months ago

Recursion Pharmaceuticals Press release: Study Update

Dec 8, 2025, 8:00 AM EST - 9 months ago

Recursion Pharmaceuticals Slides: Study Update

Dec 8, 2025, 7:32 AM EST - 9 months ago

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Dec 8, 2025, 7:30 AM EST - 9 months ago

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Dec 1, 2025, 8:30 AM EST - 9 months ago

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Nov 18, 2025, 5:30 AM EST - 9 months ago

Recursion Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 8:00 AM EST - 10 months ago

Recursion Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 8:00 AM EST - 10 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Recursion Pharmaceuticals Quarterly report: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Recursion Pharmaceuticals Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Recursion Pharmaceuticals Slides: Q3 2025

Nov 5, 2025, 6:30 AM EST - 10 months ago

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 6:28 AM EST - 10 months ago

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Sep 8, 2025, 4:05 PM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 2:30 PM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Slides: Q2 2025

Aug 5, 2025, 6:30 AM EDT - 1 year ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 29, 2025, 8:00 AM EDT - 1 year ago

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Jun 10, 2025, 3:20 PM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 10, 2025, 6:14 AM EDT - 1 year ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 6, 2025, 10:00 AM EDT - 1 year ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

May 15, 2025, 10:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: 53rd Annual JPMorgan Global Technology, Media and Communications Conference

May 13, 2025, 1:00 PM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Quarterly report: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings release: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Slides: Q1 2025

May 5, 2025, 6:00 AM EDT - 1 year ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025, 12:45 PM EDT - 1 year ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Apr 28, 2025, 8:27 AM EDT - 1 year ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2025, 8:34 PM EDT - 1 year ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 16, 2025, 8:30 AM EDT - 1 year ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Recursion to Participate in Upcoming Investor Conference

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Annual report: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Earnings release: Q4 2024

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Slides: Q4 2024

Feb 28, 2025, 6:30 AM EST - 1 year ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 24, 2025, 8:00 AM EST - 1 year ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 18, 2025, 11:00 AM EST - 1 year ago

Altitude Lab Startups Raise $154M in Capital

Feb 5, 2025, 5:24 PM EST - 1 year ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Jan 13, 2025, 10:30 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 10:30 AM EST - 1 year ago

Recursion Pharmaceuticals Slides: FY 2025

Jan 7, 2025, 9:15 AM EST - 1 year ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Jan 6, 2025, 8:30 AM EST - 1 year ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Dec 20, 2024, 4:05 PM EST - 1 year ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Dec 11, 2024, 10:00 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Bank of America Global A.I. Conference 2024

Dec 9, 2024, 7:00 PM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Status Update

Dec 9, 2024, 7:00 PM EST - 1 year ago

Recursion Pharmaceuticals Slides: Status Update

Dec 9, 2024, 6:00 PM EST - 1 year ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Nov 20, 2024, 8:00 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 7:30 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Status Update

Nov 20, 2024, 7:30 AM EST - 1 year ago

Recursion Pharmaceuticals Press release: Status Update

Nov 20, 2024, 7:00 AM EST - 1 year ago

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Nov 13, 2024, 9:08 AM EST - 1 year ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

Nov 12, 2024, 4:54 PM EST - 1 year ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Nov 6, 2024, 7:00 AM EST - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Nov 6, 2024, 2:30 AM EST - 1 year ago

Recursion Pharmaceuticals Quarterly report: Q3 2024

Nov 6, 2024, 2:30 AM EST - 1 year ago

Recursion Pharmaceuticals Earnings release: Q3 2024

Nov 6, 2024, 2:30 AM EST - 1 year ago

Recursion Pharmaceuticals Slides: Q3 2024

Oct 30, 2024, 8:22 AM EDT - 1 year ago

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Oct 10, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Oct 2, 2024, 8:32 AM EDT - 2 years ago

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Oct 2, 2024, 8:00 AM EDT - 2 years ago

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Sep 19, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Sep 17, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Sep 4, 2024, 8:00 AM EDT - 2 years ago

Recursion Pharmaceuticals Proxy statement: Proxy Filing

Sep 3, 2024, 8:11 AM EDT - 2 years ago

Recursion's blood vessel disorder drug meets main goal in mid-stage study

LoveRetailFroth Aug. 19 at 1:59 PM

$RXRX BIG SQUEEZE plays! $TEM $ARBE $AMLX 🚀

0 · Reply

NPNPNP Aug. 19 at 1:46 PM

$RXRX turd will flush after riding a real companies hype

0 · Reply

Crypto99999 Aug. 19 at 1:37 PM

$RXRX Cathie buying more???

0 · Reply

LoveRetailFroth Aug. 19 at 1:36 PM

$TEM Precision Medicine folks!!! $RXRX 🚀🚀

0 · Reply

Oatari Aug. 19 at 1:32 PM

$RXRX

0 · Reply

llGORDll Aug. 19 at 1:29 PM

$RXRX LFG

0 · Reply

Ashok1378 Aug. 19 at 12:32 PM

$RXRX

0 · Reply

Spartangio Aug. 19 at 12:02 PM

1 · Reply

LoveRetailFroth Aug. 19 at 11:57 AM

$RXRX Good Morning my Bio 💎s ☕️ $TEM $SANA $AMLX

0 · Reply

Michaela4m Aug. 19 at 11:43 AM

$RXRX

0 · Reply

Bazziggr Aug. 19 at 2:25 AM

$RXRX

2 · Reply

Floridaorange Aug. 18 at 11:19 PM

$RXRX Hodl

1 · Reply

Lh2838 Aug. 18 at 9:26 PM

$RXRX Aaron Levie on X When you hear that data is the new oil, this is ultimately what that looks like. AI has such a thirst for data that we’re entering an era where it’s valuable almost in any form. In a world of AI, information actually belongs as an asset on the balance sheet. This data sale is just one example of the implications of what that will look like. Ultimately, the way that companies manage and mine their organization’s intelligence will be one of the deciding factors for competitiveness and value creation in the future.

2 · Reply

BryGuy29 Aug. 18 at 8:32 PM

$RXRX LFG!! Up tomorrow.

0 · Reply

St0ckt0k101 Aug. 18 at 7:52 PM

$RXRX $2.92 to $3.04 now‼️ always good to buy in the high $2’s here it always recovers folks. ✅

0 · Reply

BryGuy29 Aug. 18 at 6:42 PM

$RXRX come on, go green before the close! People need to realize that this is not a biotech company. It’s a TECH company. Tech first, to discover BIO. Their system is validated. Multiple big Pharma partnerships, positive 4881, amazing talent joining their team. I guess it’ll require one more shoe to drop, which will likely be FDA giving clear registration pathway for 4881. Any day now…..

0 · Reply

JohnCohrin Aug. 18 at 5:00 PM

$RXRX another great short opportunity! Market is red and RRGB📉 is near 52 week highs!

1 · Reply

BryGuy29 Aug. 18 at 4:38 PM

$RXRX I’m smelling a reversal today. Let’s try to close GREEN !

0 · Reply

10xStacks Aug. 18 at 4:15 PM

$RXRX 2.88 Level 1 and 2.75 L2

0 · Reply

Brodman Aug. 18 at 3:58 PM

$RXRX will not be a survivor....just a brutal slow decline the next year or so. Nothing in 12 years, why now?????

0 · Reply

BryGuy29 Aug. 18 at 3:30 PM

$RXRX bought more AGAIN today. This is going to make me rich. I can feel it.

0 · Reply

Sterling100 Aug. 18 at 3:18 PM

$EOSE Anyone knows why the stock price of EOSE and $RXRX moves together? These are two totally different companies with different industry but moves almost always the same. Wiredo!

0 · Reply

Market Cap	1.66B
Revenue (ttm)	74.68M
Net Income (ttm)	-644.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-863.36%
Debt to Equity Ratio	0.01

Volume	16,340,700
Avg Vol	19,691,152
Day's Range	N/A - N/A
Shares Out	535.34M
Stochastic %K	34%
Beta	1.03
Analysts	Sell
Price Target	$6.76